French ophthalmic device company Quantel Medical has gained U.S. FDA 510(k) clearance for its Optimis Fusion™ integrated laser platform.
Glaucoma is a group of diseases that damage the eye’s optic nerve and can result in vision loss and blindness. A cataract is a clouding of the lens inside the eye, which leads to a decrease in vision and is conventionally treated with surgery. Now for the first time a system has been developed which enables clinicians to treat both conditions.
Quantel Medical’s newly cleared system integrates the company’s Optimis Fusion with its Vitra™ Monospot and Multispot pattern-scanning retina laser systems. This combined system offers comprehensive treatment options for multi-specialty practices looking to treat glaucoma, cataract and retina conditions in one laser platform. The system combines advanced selective laser trabeculoplasty (SLT) photoregeneration therapy and traditional YAG photodisruption treatments to offer ophthalmologists a versatile armamentarium for treating both cataract and glaucoma in an efficient combination platform.
“We are extremely excited to bring our breakthrough laser platform to the U.S. market,” said Jean-Marc Gendre, CEO of Quantel Medical. “The Optimis Fusion has proven to be a very attractive laser platform since introduction earlier this year in other markets. Driving the acceptance of this product introduction is the ability to combine a 532nm mono spot or multispot retina laser, a unique feature to Quantel’s laser line.”
Source: Quantel Medical, Inc., PR Newswire